U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07430059) titled 'Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant' on Feb. 10.
Brief Summary: The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight/obese participants who are otherwise healthy..
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Obesity & Overweight
Intervention:
COMBINATION_PRODUCT: Semaglutide Implant (NPM-139)
Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant ~23...